bioRxivBioinformaticsPreprint
On the applicability domain of HADDOCK3 for protein-aptamer docking: documented failure modes from a 5x7 cross-target screening matrix and a 1676 aa receptor case study (P01031)
Abstract
We screened a 5-receptor x 7-aptamer = 35-cell cross-target screening matrix with HADDOCK3 under blind ambiguous-interaction-restraint (AIR) protocols on AlphaFold-modelled receptors. The 35-cell matrix is primarily a cross-target / decoy screening matrix rather than a 35-cognate-pair benchmark: it contains an n = 4 K_D-calibration subset under matched assay conditions, at least six biological cognate or intended-cognate cells, and the remaining cells are intentional non-target pairings used to characterise score-distribution behaviour. The screen surfaced 12 operationally distinct failure modes that collapse into five broad conceptual groups. The principal case study is P01031 (complement C5, 1676 aa, [≥] 12 structural domains): all seven panel members produced positive HADDOCK3 top-1 scores under a scale-adaptive AIR. Score-term decomposition locates the anomaly in the AIR term (+217 to +268 to top-1 score). With AIR zeroed, scores fall to -131 to -74 -- the small-receptor regime. Boltz-2 cofolding chain-pair ipTM (cpi_AB) is an independent channel: P01031 shows the lowest median cpi_AB (0.211; 0/7 above the 0.5 confident-interface threshold). To our knowledge, this is an early documented case study of a 1676 aa multi-domain receptor exhibiting this signature under a blind scale-adaptive AIR workflow -- an n = 1 mechanistic case, not a statistical generalisation. We adapt the QSAR applicability-domain concept to in silico aptamer screening. We report an empirical Mode 1 mitigation, a pLDDT-aware AIR prefilter, with cohort Jaccard recovery of [~]10x. The n = 4 K_D-calibration Spearman {rho} shift is reported as exploratory cross-method convergence, not as a calibration claim.
- assay: protein structure
- research focus: benchmarking
- research focus: software / tool
- approach: statistical model
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- How AlphaFold 3 helps with multiscale drug discovery
Ratilal Akabari, William Mangione, … Ram Samudrala·bioRxiv·Oct 22, 2026
- AlphaFold3 for Structure-guided Ligand Discovery
Kartikeya M. Menon, Aakash Davasam, … Jiankun Lyu·bioRxiv·Jun 12, 2026
- Generation of appropriate protein structures for virtual screening using AlphaFold3 predicted protein-ligand complexes
Yuki Yasumitsu, Masahito Ohue·Computational and Structural Biotechnology ReportsPeer-reviewed·Jan 1, 2025
- What has AlphaFold3 learned about antibody and nanobody docking, and what remains unsolved?
Fatima N. Hitawala, Jeffrey J. Gray·mAbsPeer-reviewed·Aug 14, 2025
- An overview of data-driven HADDOCK strategies in CAPRI rounds 38-45.
Panagiotis I. Koukos, Jorge Roel‐Touris, … Alexandre M. J. J. Bonvin·Proteins Structure Function and BioinformaticsPeer-reviewed·Dec 30, 2019
- A Structural Antibody Benchmark of AlphaFold3 reveals Hallucinated Epitopes and a Bias for Orderness
Arnav Solanki, Neha Shree Maurya, … Wenjin Jim Zheng·bioRxiv·Jul 31, 2026